Activity of Fosfomycin against Extended-Spectrum-β-Lactamase-Producing Uropathogens in Patients in the Community and Hospitalized Patients | Zendy

Katherine Linsenmeyer | Zendy; Judith Strymish | Zendy; Susan Weir | Zendy; Gretchen Berg | Zendy; Stephen M. Brecher | Zendy; Kalpana Gupta | Zendy

Open Access

Activity of Fosfomycin against Extended-Spectrum-β-Lactamase-Producing Uropathogens in Patients in the Community and Hospitalized Patients

Author(s) -

Katherine Linsenmeyer,

Judith Strymish,

Susan Weir,

Gretchen Berg,

Stephen M. Brecher,

Kalpana Gupta

Publication year - 2015

Publication title -

antimicrobial agents and chemotherapy

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.07

H-Index - 259

eISSN - 1070-6283

pISSN - 0066-4804

DOI - 10.1128/aac.02614-15

Subject(s) - fosfomycin , medicine , antibiotics , microbiology and biotechnology , klebsiella , urinary system , beta lactamase , enterobacteriaceae , klebsiella pneumoniae , veterans affairs , escherichia coli , biology , biochemistry , gene

Few oral antibiotics exist for the empirical treatment of extended-spectrum β-lactamase (ESBL) urinary tract infections (UTI). In this study, we sought to determine the activity of fosfomycin against ESBL-producing uropathogens from patients at 3 Veterans Affairs (VA) facilities between 2010 and 2013. Among the ESBL uropathogens, 19.9% were fosfomycin resistant. Klebsiella species were more likely than Escherichia coli to be resistant (46% versus 4%; P < 0.001). Fosfomycin remains active against a majority of the ESBL uropathogens, although resistance among Klebsiella spp. was higher than that in previous reports.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research